Korea Exchange · Healthcare
Daewoong stock from India: price, numbers and tax
Daewoong (003090) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Daewoong at a glance
- Price
- ₩15,690.00-₩10.00 (0.06%)
- Market cap
- ₩659.56B
- Day range
- ₩15,300.00 – ₩15,690.00
- P/E
- 3.38
- Dividend yield
- 1.27%
- Volume
- 84.23K
- 1 month
- -4.50%
- 6 months
- -29.32%
- YTD
- -28.84%
- 1 year
- -28.03%
- 5 years
- -50.89%
Daewoong statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩2.1T | ₩1.9T | ₩1.8T | ₩1.7T | ₩1.5T |
| Gross profit | ₩1.1T | ₩1.0T | ₩931.2B | ₩899.7B | ₩763.2B |
| Operating income | ₩260.5B | ₩281.9B | ₩195.9B | ₩207.3B | ₩182.5B |
| Net income | ₩175.1B | ₩57.9B | ₩152.7B | ₩102.6B | ₩78.7B |
| Earnings per share | ₩4,280.00 | ₩1,416.17 | ₩3,691.68 | ₩2,466.88 | ₩1,894.69 |
| EBITDA | ₩323.4B | ₩182.1B | ₩270.3B | ₩211.6B | ₩233.0B |
| Total assets | ₩3.2T | ₩2.7T | ₩2.4T | ₩2.2T | ₩1.9T |
| Total debt | ₩878.2B | ₩682.6B | ₩448.8B | ₩445.1B | ₩445.5B |
| Cash and short-term investments | ₩285.8B | ₩264.1B | ₩267.2B | ₩386.7B | ₩387.9B |
| Shareholders' equity | ₩1.2T | ₩996.5B | ₩934.8B | ₩828.8B | ₩730.6B |
| Operating cash flow | ₩257.6B | ₩162.4B | ₩205.7B | ₩149.1B | ₩133.2B |
| Free cash flow | −₩37.2B | −₩173.9B | −₩23.3B | ₩31.5B | ₩17.7B |
| Capital expenditure | −₩294.8B | −₩336.3B | −₩229.0B | −₩117.6B | −₩115.5B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Chong Kun Dang Pharmaceutical | 185750.KS | ₩65,900.00 | ₩868.30B |
| Dong-A Socio | 000640.KS | ₩93,000.00 | ₩626.13B |
| JW | 096760.KS | ₩4,105.00 | ₩284.03B |
| Korea United Pharm | 033270.KS | ₩17,860.00 | ₩257.93B |
| Yungjin Pharm. | 003520.KS | ₩1,035.00 | ₩189.29B |
| Chong Kun Dang | 001630.KS | ₩37,250.00 | ₩177.33B |
| Ilsung Is | 003120.KS | ₩22,350.00 | ₩160.07B |
| Daihan Pharmaceutical | 023910.KQ | ₩25,850.00 | ₩152.00B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Daewoong from India
What Daewoong does
Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Daewoong operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Daewoong shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.